{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:25:29Z","timestamp":1790810729585,"version":"4.1.0"},"reference-count":25,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,5,18]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.126.272521","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:20:11Z","timestamp":1782397211000},"page":"1413-1420","source":"Crossref","is-referenced-by-count":1,"title":["SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [\n                    <sup>68<\/sup>\n                    Ga]Ga-DOTATOC and [\n                    <sup>68<\/sup>\n                    Ga]Ga-SSO120 with [\n                    <sup>18<\/sup>\n                    F]FDG PET"],"prefix":"10.2967","volume":"67","author":[{"given":"Alina T.","family":"K\u00fcper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalith Kumar","family":"Shiyam Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00edc","family":"Djaileb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Roschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieva","family":"Ciuciulkaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Carrilho","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Welt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Hammersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026091707501241000_67.9.1413.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026091707501241000_67.9.1413.2","unstructured":"https:\/\/register.awmf.org\/assets\/guidelines\/032-045OLl_S3_Mammakarzinom_2021-07.pdf."},{"key":"2026091707501241000_67.9.1413.3","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2000.18.20.3495","article-title":"Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations","volume":"18","author":"Avril","year":"2000","journal-title":"J Clin Oncol."},{"key":"2026091707501241000_67.9.1413.4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/1754-9485.13342","article-title":"Diagnostic value of 68Ga\u2010DOTATATE PET\u2010CT imaging for staging of ER+\/PR+ HER2\u2013breast cancer patients with metastatic disease: comparison with conventional imaging with bone scan, diagnostic CT and 18F\u2010FDG PET\u2010CT in a prospective pilot trial","volume":"66","author":"Nguyen","year":"2022","journal-title":"J Med Imaging Radiat Oncol."},{"key":"2026091707501241000_67.9.1413.5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41698-025-00938-1","article-title":"Emerging innovations in theranostics for pancreatic neuroendocrine tumors","volume":"9","author":"Karimi","year":"2025","journal-title":"npj Precision Oncol."},{"key":"2026091707501241000_67.9.1413.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607761103"},{"key":"2026091707501241000_67.9.1413.7","first-page":"502","article-title":"Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists","volume":"47","author":"Cescato","year":"2006","journal-title":"J Nucl Med."},{"key":"2026091707501241000_67.9.1413.8","doi-asserted-by":"crossref","first-page":"101797","DOI":"10.1016\/j.beem.2023.101797","article-title":"New horizon of radiopharmaceuticals in management of neuroendocrine tumors","volume":"37","author":"Haq","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"2026091707501241000_67.9.1413.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0099"},{"key":"2026091707501241000_67.9.1413.10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13550-021-00765-y","article-title":"Evaluation of [68Ga]Ga-PSMA PET\/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision","volume":"11","author":"Weber","year":"2021","journal-title":"EJNMMI Res."},{"key":"2026091707501241000_67.9.1413.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10166-8"},{"key":"2026091707501241000_67.9.1413.12","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy182"},{"key":"2026091707501241000_67.9.1413.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269688"},{"key":"2026091707501241000_67.9.1413.14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology."},{"key":"2026091707501241000_67.9.1413.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2026091707501241000_67.9.1413.16","first-page":"3997","article-title":"Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer","volume":"34","author":"Frati","year":"2014","journal-title":"Anticancer Res."},{"key":"2026091707501241000_67.9.1413.17","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin recepter PET ligands: the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311\u2013331."},{"key":"2026091707501241000_67.9.1413.18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CAD.0b013e32835a7e29","article-title":"Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]","volume":"24","author":"Seitz","year":"2013","journal-title":"Anticancer Drugs."},{"key":"2026091707501241000_67.9.1413.19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40644-022-00465-3","article-title":"Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms","volume":"22","author":"Iravani","year":"2022","journal-title":"Cancer Imaging."},{"key":"2026091707501241000_67.9.1413.20","doi-asserted-by":"crossref","first-page":"e233408","DOI":"10.1148\/radiol.233408","article-title":"Dotatate PET\/CT and 225Ac-Dotatate therapy for somatostatin receptor\u2013expressing metastatic breast cancer","volume":"312","author":"Ulaner","year":"2024","journal-title":"Radiology."},{"key":"2026091707501241000_67.9.1413.21","doi-asserted-by":"crossref","first-page":"9988","DOI":"10.1038\/s41598-025-94578-x","article-title":"Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer","volume":"15","author":"Lynch","year":"2025","journal-title":"Sci Rep."},{"key":"2026091707501241000_67.9.1413.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1828"},{"key":"2026091707501241000_67.9.1413.23","doi-asserted-by":"crossref","first-page":"102940","DOI":"10.1016\/j.ctrv.2025.102940","article-title":"Radioligand therapy in metastatic breast cancer: harnessing precision oncology","volume":"136","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"2026091707501241000_67.9.1413.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199760"},{"key":"2026091707501241000_67.9.1413.25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/aps.2009.59","article-title":"The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells","volume":"30","author":"He","year":"2009","journal-title":"Acta Pharmacol Sin."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:51:36Z","timestamp":1789656696000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.126.272521"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272521","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}